(Q36150541)

12 August 2017

1 reference

title

The safety of cannabinoids for the treatment of multiple sclerosis (English)

1 reference

12 August 2017

0 references

Paul F Smith

1

1 reference

PubMed ID

15934852

12 August 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Expert Opinion on Drug Safety

12 August 2017

1 reference

12 August 2017

4

1 reference

12 August 2017

443-456

1 reference

12 August 2017

3

1 reference

12 August 2017

Cannabis and the brain

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

The endocannabinoid system as a target for therapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

CB1 cannabinoid receptors and on-demand defense against excitotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Cannabinoid receptors and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Retrograde signaling by endocannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Cannabinoids control spasticity and tremor in a multiple sclerosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

The perceived effects of smoked cannabis on patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Cannabinoids for the treatment of multiple sclerosis: no smoke without fire?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Safety, tolerability, and efficacy of orally administered cannabinoids in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

The effect of cannabis on tremor in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Airway effects of marijuana, cocaine, and other inhaled illicit agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Airway inflammation in young marijuana and tobacco smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Effects of smoking marijuana, tobacco or cocaine alone or in combination on DNA damage in human alveolar macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

The respiratory effects of cannabis dependence in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Heavy habitual marijuana smoking does not cause an accelerated decline in FEV1 with age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Marijuana. Respiratory tract effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Lung disease induced by drug addiction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Control of the cell survival/death decision by cannabinoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Neuropsychological performance in long-term cannabis users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Residual neuropsychologic effects of cannabis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Modulation of the effects of alcohol on driving-related psychomotor skills by chronic exposure to cannabis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

The acute effects of tetrahydrocannabinol on auditory threshold and frequency resolution in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Auditory-Evoked Potentials and Selective Attention: Different Ways of Information Processing in Cannabis Users and Controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Reduced binocular depth inversion in regular cannabis users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Is the party over? Cannabis and juvenile psychiatric disorder: the past 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Cannabis use and psychosocial adjustment in adolescence and young adulthood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Adverse effects of cannabis on health: an update of the literature since 1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Psychological and social sequelae of cannabis and other illicit drug use by young people: a systematic review of longitudinal, general population studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Cannabis abuse as a risk factor for depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Alcohol, cannabis and tobacco use among Australians: a comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Does marijuana use have residual adverse effects on self-reported health measures, socio-demographics and quality of life? A monozygotic co-twin control study in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Psychiatric effects of cannabis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Cannabis use and psychosis: a longitudinal population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Cannabis use and the risk of later schizophrenia: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Cannabis use and psychosis: a review of clinical and epidemiological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Causal association between cannabis and psychosis: examination of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Differential effects on facets of attention in adolescents prenatally exposed to cigarettes and marihuana

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Effects of prenatal marijuana on response inhibition: an fMRI study of young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Prenatal cannabinoid and gene expression for neural adhesion molecule L1 in the fetal rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Cannabis, cannabinoids and reproduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Potent effects of a selective cannabinoid receptor agonist on some guinea pig medial vestibular nucleus neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Acute cardiovascular fatalities following cannabis use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Effect of cannabinoid ingestion (in the form of bhang) on the immune system of high school and university students

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Abstinence symptoms following oral THC administration to humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Abstinence symptoms following smoked marijuana in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Marijuana abstinence effects in marijuana smokers maintained in their home environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

A review of the published literature into cannabis withdrawal symptoms in human users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Cannabinoid receptor-1 activation suppresses inhibitory synaptic activity in human dentate gyrus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.443

21 January 2018

Identifiers

DOI

10.1517/14740338.4.3.443

1 reference

12 August 2017

1 reference

PubMed ID

15934852